Pro-Inflammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of Erythropoiesis

Anemia of cancer and chronic inflammatory diseases is a frequent complication affecting quality of life. For cancer patients it represents a particularly bad prognostic. Low level of erythropoietin is considered as one of the causes of anemia in these pathologies. The deficiency in erythropoietin production results from pro-inflammatory cytokines effect. However, few data is available concerning molecular mechanisms involved in cytokine-mediated anemia. Some recent publications have demonstrated the direct effect of pro-inflammatory cytokines on cell differentiation towards erythroid pathway, without erythropoietin defect. This suggested that pro-inflammatory cytokine-mediated signaling pathways affect erythropoietin activity. They could interfere with erythropoietin-mediated signaling pathways, inducing early apoptosis and perturbing the expression and regulation of specific transcription factors involved in the control of erythroid differentiation. In this review we summarize the effect of tumor necrosis factor (TNF)α, TNF-related apoptosis-inducing ligand (TRAIL), and interferon (IFN)-γ on erythropoiesis with a particular interest for molecular feature.

[1]  W. Jelkmann,et al.  Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. , 1997, The American journal of physiology.

[2]  K. Ozawa,et al.  A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. , 2000, Blood.

[3]  F. Watzinger,et al.  Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. , 2001, International journal of radiation oncology, biology, physics.

[4]  R. Kurzrock.  The role of cytokines in cancer‐related fatigue , 2001, Cancer.

[5]  C. Winterbourn.  Oxidative denaturation in congenital hemolytic anemias: the unstable hemoglobins. , 1990, Seminars in hematology.

[6]  R. Gillet,et al.  Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  Y Nagata,et al.  Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. , 1998, Blood.

[8]  P. Waterhouse,et al.  miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. , 2009, Blood.

[9]  Aaron N. Chang,et al.  GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Herr,et al.  JNK/SAPK activity is not sufficient for anticancer therapy‐induced apoptosis involving CD95‐L, TRAIL and TNF‐α , 1999, International journal of cancer.

[11]  E. Sen,et al.  Ebselen abrogates TNFα induced pro‐inflammatory response in glioblastoma , 2009, Molecular oncology.

[12]  Muller Fabbri,et al.  Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock1 , 2007, The Journal of Immunology.

[13]  E. Dessypris,et al.  Inhibition of human erythroid colony‐forming units by interleukin‐1 is mediated by gamma interferon , 1992, Journal of cellular physiology.

[14]  B. Pace,et al.  Stat3β Inhibits γ-Globin Gene Expression in Erythroid Cells* , 2002, The Journal of Biological Chemistry.

[15]  S. Piantadosi,et al.  Decreased erythropoietin response in patients with the anemia of cancer. , 1990, The New England journal of medicine.

[16]  Huiling Xue,et al.  MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. , 2008, Blood.

[17]  J. Caro,et al.  Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. , 1989, Blood.

[18]  Masayuki Yamamoto,et al.  Roles of Hematopoietic Transcription Factors GATA-1 and GATA-2 in the Development of Red Blood Cell Lineage , 2002, Acta Haematologica.

[19]  Xiaowu Gai,et al.  A GATA-1-regulated microRNA locus essential for erythropoiesis , 2008, Proceedings of the National Academy of Sciences.

[20]  S. Jacobsen,et al.  Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. , 1995, Blood.

[21]  J. Lawrence,et al.  Early events in erythroid differentiation: accumulation of the acidic peroxidoxin (PRP/TSA/NKEF-B). , 1995, The Biochemical journal.

[22]  G. Blobel,et al.  CREB-Binding Protein Acetylates Hematopoietic Transcription Factor GATA-1 at Functionally Important Sites , 1999, Molecular and Cellular Biology.

[23]  S. Sawyer,et al.  Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines. , 2004, Blood.

[24]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[25]  N. Rekhtman,et al.  Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. , 1999, Genes & development.

[26]  E. Alnemri,et al.  TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. , 2000, Blood.

[27]  Kamaleldin E Elagib,et al.  RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. , 2003, Blood.

[28]  A. Schechter,et al.  Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation. , 2000, Experimental hematology.

[29]  H. Beug,et al.  The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. , 1999, Blood.

[30]  N. Young,et al.  Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[32]  Á. Apáti,et al.  Activation of Raf/ERK1/2 MAP kinase pathway is involved in GM-CSF-induced proliferation and survival but not in erythropoietin-induced differentiation of TF-1 cells. , 2001, Cellular signalling.

[33]  G. Mantovani,et al.  Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. , 2005, Blood.

[34]  I. Wilson,et al.  Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.

[35]  M. Angelopoulou,et al.  Disease-Related Anemia in Chronic Lymphocytic Leukemia Is Not Due to Intrinsic Defects of Erythroid Precursors: A Possible Pathogenetic Role for Tumor Necrosis Factor-Alpha , 2009, Acta Haematologica.

[36]  P. Contu,et al.  Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: Correlation with stage and performance status , 2002, International journal of cancer.

[37]  L. Devy,et al.  Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells. , 1996, Biochemical pharmacology.

[38]  W. Vainchenker,et al.  Erythropoietin induces the association of phosphatidylinositol 3'-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor. , 1993, European journal of biochemistry.

[39]  M. McMahon,et al.  Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. , 1991, The Journal of biological chemistry.

[40]  L. Moldawer,et al.  Cachectin/tumor necrosis factor‐α alters red blood cell kinetics and induces anemia in vivo , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  H. Deeg,et al.  Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. , 2001, Blood.

[42]  T. Miyawaki,et al.  Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. , 1992, Blood.

[43]  S. Srinivasula,et al.  Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1 , 1999, Nature.

[44]  Y. Ravindranath,et al.  Hemoglobin autoxidation and regulation of endogenous H2O2 levels in erythrocytes. , 2005, Free radical biology & medicine.

[45]  E. Nishida,et al.  Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3. , 1997, Blood.

[46]  P. Secchiero,et al.  TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. , 2004, Blood.

[47]  J. Groopman,et al.  Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.

[48]  N. Young,et al.  Gamma-Interferon Gene Expression in the Bone Marrow of Patients with Aplastic Anemia , 1994, Annals of Internal Medicine.

[49]  S. Orkin,et al.  Transcriptional regulation of erythropoiesis: an affair involving multiple partners , 2002, Oncogene.

[50]  J. Ulaszek,et al.  Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  H. Beug,et al.  Protein Kinase C α Controls Erythropoietin Receptor Signaling* , 2000, The Journal of Biological Chemistry.

[52]  H. Papadaki,et al.  Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. , 2002, Blood.

[53]  I. Herr,et al.  TRAIL/Apo‐2‐ligand‐induced apoptosis in human T cells , 1998, European journal of immunology.

[54]  O. Shirihai,et al.  UCP2 Modulates Cell Proliferation through the MAPK/ERK Pathway during Erythropoiesis and Has No Effect on Heme Biosynthesis* , 2008, Journal of Biological Chemistry.

[55]  J. Caro,et al.  Anemia as an independent prognostic factor for survival in patients with cancer , 2001 .

[56]  Brian Leyland-Jones,et al.  Breast cancer trial with erythropoietin terminated unexpectedly. , 2003, The Lancet. Oncology.

[57]  C. Epstein,et al.  Absence of Mitochondrial Superoxide Dismutase Results in a Murine Hemolytic Anemia Responsive to Therapy with a Catalytic Antioxidant , 2001, The Journal of experimental medicine.

[58]  D. Follmann,et al.  Intracellular interferon-γ in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia , 2002 .

[59]  S. Amadori,et al.  Cancer‐related fatigue , 2003, Cancer.

[60]  H. Masutani.  Oxidative stress response and signaling in hematological malignancies and HIV infection. , 2000, International journal of hematology.

[61]  M. Goldberg,et al.  Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. , 1992, Blood.

[62]  L. Bendall,et al.  Bone marrow fibroblast exposure to the inflammatory cytokines tumor necrosis factor-alpha and interferon-gamma increases adhesion of acute myeloid leukemia cells and alters the adhesive mechanism. , 1997, Experimental hematology.

[63]  R. Salgia,et al.  Hematopoietic growth factors signal through the formation of reactive oxygen species. , 1999, Blood.

[64]  Koichiro Muta,et al.  Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. , 2007, Biochemical and biophysical research communications.

[65]  F. Lanza,et al.  Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. , 2005, The American journal of pathology.

[66]  E. Lapetina,et al.  Erythropoietin induces p21ras activation and p120GAP tyrosine phosphorylation in human erythroleukemia cells. , 1992, The Journal of biological chemistry.

[67]  R. Casero,et al.  Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. , 2006, Cancer research.

[68]  S. Kajigaya,et al.  Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. , 2006, Blood.

[69]  Yohnosuke Kobayashi,et al.  Requirement of thrombopoietin-induced activation of ERK for megakaryocyte differentiation and of p38 for erythroid differentiation , 2001, Annals of Hematology.

[70]  S. Alıcı,et al.  Anemia in Oncology Practice: Relation to Diseases and Their Therapies , 2002, American journal of clinical oncology.

[71]  S. Orkin,et al.  ABC‐me: a novel mitochondrial transporter induced by GATA‐1 during erythroid differentiation , 2000, The EMBO journal.

[72]  A. Bacigalupo,et al.  Analysis at the clonal level of T-cell phenotype and functions in severe aplastic anemia patients. , 1991, Blood.

[73]  H. Beug,et al.  Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1. , 2007, The EMBO journal.

[74]  M. Diederich,et al.  GATA‐1: Friends, Brothers, and Coworkers , 2004, Annals of the New York Academy of Sciences.

[75]  Young,et al.  Fas Antigen Expression on CD 34 ’ Human Marrow Cells Is Induced by Interferon y and Tumor Necrosis Factor ( Y and Potentiates Cytokine-Mediated Hematopoietic Suppression In Vitro , 2000 .

[76]  M. von Lindern,et al.  Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. , 2004, Blood.

[77]  J. Jordan,et al.  Erythropoietin stimulates transcription of the TAL1/SCL gene and phosphorylation of its protein products , 1995, The Journal of Biological Chemistry.

[78]  G. Roodman,et al.  Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. , 1987, Experimental hematology.

[79]  K. Muta,et al.  Stem cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation. , 1995, Blood.

[80]  M. Biffoni,et al.  Multiple Members of the TNF Superfamily Contribute to IFN-γ-Mediated Inhibition of Erythropoiesis1 , 2005, The Journal of Immunology.

[81]  P. Kazembe,et al.  Comparison of Serum and Cell-Specific Cytokines in Humans , 2001, Clinical Diagnostic Laboratory Immunology.

[82]  S. Wade,et al.  Prevalence and outcomes of anemia in cancer: a systematic review of the literature. , 2004, The American journal of medicine.

[83]  M. Andreeff,et al.  Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies , 1997, British journal of haematology.

[84]  M. Diederich,et al.  Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1. , 2006, Cancer letters.

[85]  J. Spivak.  The anaemia of cancer: death by a thousand cuts , 2005, Nature Reviews Cancer.

[86]  R. Means,et al.  Effects of oxidative stress on human erythroid colony formation: modulation by γ-interferon , 2003 .

[87]  S. Kajigaya,et al.  Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. , 2004, Blood.

[88]  J. Price,et al.  Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. , 1998, Blood.

[89]  M. Rosenblum,et al.  Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.

[90]  Masayuki Yamamoto,et al.  GATA1 Function, a Paradigm for Transcription Factors in Hematopoiesis , 2005, Molecular and Cellular Biology.

[91]  M. Biffoni,et al.  MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis , 2009, Haematologica.

[92]  S. Orkin,et al.  Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. , 1998, Genes & development.

[93]  Z. Zhao,et al.  Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways , 2000, British journal of haematology.

[94]  W. Jelkmann,et al.  Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA‐2 and NF‐κB , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[95]  N. Young,et al.  Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. , 1995, Blood.

[96]  D. Amanatullah,et al.  PU.1 inhibits the erythroid program by binding to GATA‐1 on DNA and creating a repressive chromatin structure , 2005, The EMBO journal.

[97]  R. Means.  Pathogenesis of the anemia of chronic disease: A cytokine‐mediated anemia , 1995, Stem cells.

[98]  R. Greenwald,et al.  Oxygen radicals, inflammation, and arthritis: pathophysiological considerations and implications for treatment. , 1991, Seminars in arthritis and rheumatism.

[99]  M. Diederich,et al.  Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation. , 2008, Biochemical pharmacology.

[100]  S. Orkin,et al.  CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[101]  I. Wilson,et al.  Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.

[102]  S. Srinivasula,et al.  Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1 , 2003, Cell Death and Differentiation.

[103]  A. Vannucchi,et al.  Inhibition of erythropoietin production in vitro by human interferon gamma , 1994, British journal of haematology.

[104]  A. Medvedev,et al.  Persistent Nuclear Factor-κB Activation in Ucp2-/- Mice Leads to Enhanced Nitric Oxide and Inflammatory Cytokine Production* , 2005, Journal of Biological Chemistry.

[105]  A. Schechter,et al.  Levels of GATA-1/GATA-2 transcription factors modulate expression of embryonic and fetal hemoglobins. , 2000, Gene.

[106]  F. Dammacco,et al.  Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. , 2002, Blood.

[107]  S. Davidge,et al.  The role of reactive nitrogen/oxygen intermediates in cytokine-induced trophoblast apoptosis. , 1999, Placenta.

[108]  M. Rymaszewski,et al.  TRAIL Death Pathway Expression and Induction in Thyroid Follicular Cells* , 1999, The Journal of Biological Chemistry.

[109]  Yan Liu,et al.  The gift of Gab , 2002, FEBS letters.

[110]  M. Marrero,et al.  Erythropoietin receptor-operated Ca2+ channels: Activation by phospholipase C-γ1 , 1998 .

[111]  M. Koury,et al.  Mitogen-activated protein kinase mediates erythropoietin-induced phosphorylation of the TAL1/SCL transcription factor in murine proerythroblasts. , 1999, The Biochemical journal.

[112]  T. Kodama,et al.  A GATA‐specific inhibitor (K‐7174) rescues anemia induced by IL‐1β, TNF‐α, or l‐NMMA , 2003 .

[113]  C. Rübe,et al.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial , 2003, The Lancet.

[114]  Tariq Enver,et al.  High GATA-2 expression inhibits human hematopoietic stem and progenitor cell function by effects on cell cycle. , 2009, Blood.

[115]  H. Beug,et al.  Raf-1 Antagonizes Erythroid Differentiation by Restraining Caspase Activation , 2002, The Journal of experimental medicine.

[116]  R. Shivdasani.  Molecular and Transcriptional Regulation of Megakaryocyte Differentiation , 2001, Stem cells.

[117]  Saijuan Chen,et al.  Mir-144 selectively regulates embryonic -hemoglobin synthesis during primitive erythropoiesis , 2008 .

[118]  J. Abrahamsson,et al.  Interferon γ and tumour necrosis factor α in relation to anaemia and prognosis in childhood cancer , 2005, Acta paediatrica.

[119]  J. Myklebust,et al.  Protein kinase C-α isoform is involved in erythropoietin-induced erythroid differentiation of CD34+ progenitor cells from human bone marrow , 2000 .

[120]  V. Ogryzko,et al.  Regulation of activity of the transcription factor GATA-1 by acetylation , 1998, Nature.

[121]  S. Krantz,et al.  Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. , 1998, Blood.

[122]  H. Lodish,et al.  Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. , 2001, Blood.

[123]  J. Schrader,et al.  Activation of the stress-activated protein kinases by multiple hematopoietic growth factors with the exception of interleukin-4. , 1997, Blood.

[124]  C. Croce,et al.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[125]  Shin-Chen Hou,et al.  Erythroid Gene Suppression by NF-κB* , 2003, Journal of Biological Chemistry.

[126]  A. Sytkowski,et al.  Erythropoietin Activates Two Distinct Signaling Pathways Required for the Initiation and the Elongation of c-myc * , 2001, The Journal of Biological Chemistry.

[127]  P. Guiraud,et al.  Oxidative stress involvement in chemically induced differentiation of K562 cells. , 2000, Free radical biology & medicine.

[128]  C. Lacombe,et al.  Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. , 2003, Blood.

[129]  S. Ghaffari,et al.  Foxo3 is required for the regulation of oxidative stress in erythropoiesis. , 2007, The Journal of clinical investigation.

[130]  P. Krammer,et al.  Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage , 1998, European journal of immunology.

[131]  H. Lodish,et al.  Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. , 2006, Blood.

[132]  M. Arcasoy,et al.  Co‐operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor , 2005, British journal of haematology.

[133]  T. Koike,et al.  Tumor necrosis factor-α inhibits generation of glycophorin A+ cells by CD34+ cells , 2002 .

[134]  K. Knight,et al.  Prevalence and outcomes of anemia in surgery: a systematic review of the literature. , 2004, The American journal of medicine.

[135]  M. Diederich,et al.  The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation. , 2009, International journal of oncology.